219 related articles for article (PubMed ID: 37842562)
21. Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth.
Ding XY; Ding J; Wu K; Wen W; Liu C; Yan HX; Chen C; Wang S; Tang H; Gao CK; Guo LN; Cao D; Li Z; Feng GS; Wang HY; Xu ZF
Oncogene; 2012 Jun; 31(23):2899-906. PubMed ID: 22002304
[TBL] [Abstract][Full Text] [Related]
22. Rivaroxaban Suppresses Atherosclerosis by Inhibiting FXa-Induced Macrophage M1 Polarization-Mediated Phenotypic Conversion of Vascular Smooth Muscle Cells.
Ma Y; Zhang Y; Qiu C; He C; He T; Shi S; Liu Z
Front Cardiovasc Med; 2021; 8():739212. PubMed ID: 34869643
[No Abstract] [Full Text] [Related]
23. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
24. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
25. Advanced Glycation End Products Induce Atherosclerosis via RAGE/TLR4 Signaling Mediated-M1 Macrophage Polarization-Dependent Vascular Smooth Muscle Cell Phenotypic Conversion.
Xing Y; Pan S; Zhu L; Cui Q; Tang Z; Liu Z; Liu F
Oxid Med Cell Longev; 2022; 2022():9763377. PubMed ID: 35069982
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory Therapeutic Effects of Curcumin on M1/M2 Macrophage Polarization in Inflammatory Diseases.
Abdollahi E; Johnston TP; Ghaneifar Z; Vahedi P; Goleij P; Azhdari S; Moghaddam AS
Curr Mol Pharmacol; 2023; 16(1):2-14. PubMed ID: 35331128
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis.
Real C; Remédio L; Caiado F; Igreja C; Borges C; Trindade A; Pinto-do-Ó P; Yagita H; Duarte A; Dias S
PLoS One; 2011 Apr; 6(4):e18323. PubMed ID: 21483741
[TBL] [Abstract][Full Text] [Related]
28. Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine Expression.
Shen Z; Liu Y; Dewidar B; Hu J; Park O; Feng T; Xu C; Yu C; Li Q; Meyer C; Ilkavets I; Müller A; Stump-Guthier C; Munker S; Liebe R; Zimmer V; Lammert F; Mertens PR; Li H; Ten Dijke P; Augustin HG; Li J; Gao B; Ebert MP; Dooley S; Li Y; Weng HL
Am J Pathol; 2016 Jul; 186(7):1874-1889. PubMed ID: 27171900
[TBL] [Abstract][Full Text] [Related]
29. The role of macrophages in rosacea: implications for targeted therapies.
Liu Y; Zhou Y; Chu C; Jiang X
Front Immunol; 2023; 14():1211953. PubMed ID: 37691916
[TBL] [Abstract][Full Text] [Related]
30. Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity.
Li JL; Jubb AM; Harris AL
Future Oncol; 2010 Jul; 6(7):1099-103. PubMed ID: 20624122
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological targets of metabolism in disease: Opportunities from macrophages.
Castegna A; Gissi R; Menga A; Montopoli M; Favia M; Viola A; Canton M
Pharmacol Ther; 2020 Jun; 210():107521. PubMed ID: 32151665
[TBL] [Abstract][Full Text] [Related]
32. Macrophages heterogeneity in atherosclerosis - implications for therapy.
Wilson HM
J Cell Mol Med; 2010 Aug; 14(8):2055-65. PubMed ID: 20629993
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Delta-like Ligand 4 enhances the radiosensitivity and inhibits migration in cervical cancer via the reversion of epithelial-mesenchymal transition.
Yang SS; Yu DY; Du YT; Wang L; Gu L; Zhang YY; Xiao M
Cancer Cell Int; 2020; 20():344. PubMed ID: 32742191
[TBL] [Abstract][Full Text] [Related]
34. High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer.
Kim Y; Byeon SJ; Hur J; Lee K; Kim D; Ahn JH; Lee SH; You WK; Kim ST; Park SH; Kang WK; Kim KM; Lee J
J Cancer; 2019; 10(14):3172-3178. PubMed ID: 31289587
[No Abstract] [Full Text] [Related]
35. Systemic Expression of Notch Ligand Delta-Like 4 during Mycobacterial Infection Alters the T Cell Immune Response.
Schaller MA; Allen RM; Kimura S; Day CL; Kunkel SL
Front Immunol; 2016; 7():527. PubMed ID: 27933064
[TBL] [Abstract][Full Text] [Related]
36. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer.
Jubb AM; Soilleux EJ; Turley H; Steers G; Parker A; Low I; Blades J; Li JL; Allen P; Leek R; Noguera-Troise I; Gatter KC; Thurston G; Harris AL
Am J Pathol; 2010 Apr; 176(4):2019-28. PubMed ID: 20167860
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma.
Haller BK; Bråve A; Wallgard E; Roswall P; Sunkari VG; Mattson U; Hallengärd D; Catrina SB; Hellström M; Pietras K
Oncogene; 2010 Jul; 29(30):4276-86. PubMed ID: 20498640
[TBL] [Abstract][Full Text] [Related]
38. An Overview on Macrophage Targeting: A Promising Approach.
Vemuri VD; Kushwaha R; Gowri G; Mathala N; Nalla S; Allam S; Lekhya G
Crit Rev Ther Drug Carrier Syst; 2023; 40(5):47-92. PubMed ID: 37522549
[TBL] [Abstract][Full Text] [Related]
39. Macrophage reprogramming for therapy.
Bart VMT; Pickering RJ; Taylor PR; Ipseiz N
Immunology; 2021 Jun; 163(2):128-144. PubMed ID: 33368269
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
